Long‐term efficacy of the sodium–glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome

Long‐term efficacy of the sodium–glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome

Abstract Type A insulin resistance (IR) syndrome is a severe IR form caused by insulin receptor (INSR) gene defects. Antidiabetic drugs, including high‐dose insulin and insulin‐sensitizing agents, often fail to control associated hyperglycemia. Therapy with recombinant human insulin‐like growth fact...

Full description

Bibliographic Details
Main Authors: Shuichi Nagashima, Tetsuji Wakabayashi, Naoko Saito, Manabu Takahashi, Kenta Okada, Ken Ebihara, Shun Ishibashi
Format: Article
Language:English
Published: Wiley 2020-09-01
Series:Journal of Diabetes Investigation
Subjects:
Ipragliflozin
Sodium–glucose cotransporter 2 inhibitor
Type A insulin resistance syndrome
Online Access:https://doi.org/10.1111/jdi.13241

Internet

https://doi.org/10.1111/jdi.13241

Similar Items